Home
ACE Reports
All Specialties All Specialties All Specialties Arthroplasty Arthroplasty Arthroplasty Evidence Based Medicine Evidence Based Medicine Evidence Based Medicine Foot & Ankle Foot & Ankle Foot & Ankle General Orthopaedics General Orthopaedics General Orthopaedics Hand & Wrist Hand & Wrist Hand & Wrist Metabolic Disorders Metabolic Disorders Metabolic Disorders Osteoarthritis Osteoarthritis Osteoarthritis Pediatric Orthopaedics Pediatric Orthopaedics Pediatric Orthopaedics Peri-Operative Peri-Operative Peri-Operative Physical Therapy & Rehab Physical Therapy & Rehab Physio & Rehab Shoulder & Elbow Shoulder & Elbow Shoulder & Elbow Spine Spine Spine Sports Medicine Sports Medicine Sports Medicine Trauma Trauma Trauma Tumour Tumour Tumour Author Interviews Author Interviews Author Interview Conference Report Conference Report Conference Reports
Original Content
News
Multimedia
About
Search
Home
ACE Reports
Arthroplasty Evidence Based Medicine Foot & Ankle General Orthopaedics Hand & Wrist Metabolic Disorders Osteoarthritis Pediatric Orthopaedics Peri-Operative Physical Therapy & Rehab Shoulder & Elbow Spine Sports Medicine Trauma Tumour Author Interviews Conference Report
Original Content
News
Multimedia
About
Search
Previous Ace Report Comparison of three different hamstring ACL fixation devices Next Ace Report Comparison of three different hamstring ACL fixation devices
Ace Report Cover
Osteoarthritis
Glucosamine sulphate, a controversial treatment for osteoarthritis
Reprints
Cite This
Reprints
Cite This
AceReport Image
Osteoarthritis
Glucosamine sulphate, a controversial treatment for osteoarthritis
Osteoarthritis Cartilage. 2009 Apr;17(4):427-32. Epub 2008 Oct 9
Contributing Authors

RM Rozendaal EJ Uitterlinden GJ van Osch EH Garling SP Willemsen AZ Ginai JA Verhaar H Weinans BW Koes SM Bierma-Zeinstra

222 patients with osteoarthritis of the hip were randomized to receive 1500 mg of glucosamine sulphate (GS) or a placebo daily to determine which subgroups would benefit the most from GS treatment. The 24 month results from this trial indicated that GS treatment provided no improvements in WOMAC pain and function scores or joint space narrowing when compared to the placebo group. Therefore, glucosamine was no better than placebo in reducing symptoms and progression of osteoarthritis of the hip and had no effect based on type and severity of OA.

Unlock the full article

Get unlimited access to OrthoEvidence with a free trial
Start Trial

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or continue reading this full article
Register Now
AskOE
Search
Close Search Window
Welcome Back!
Forgot Password?
Create an Account

Account will be affiliated with

OR
Forgot Password?
OR
Check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see the email, please check your spam or junk folder.

For further assistance, contact our support team.

Cite this Ace Report

OrthoEvidence. Glucosamine sulphate, a controversial treatment for osteoarthritis. ACE Report. 2013;3(5):78. Available from: https://myorthoevidence.com/AceReport/Report/

Copy Citation
Share this Ace Report